Drug Profile
Pneumococcal 23-valent vaccine - Sinovac Biotech
Alternative Names: 23-valent pneumococcal polysaccharide vaccine - Sinovac Biotech; 23-valent PPV - Sinovac; PPV-23Latest Information Update: 05 May 2022
Price :
$50
*
At a glance
- Originator Sinovac Biotech
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pneumococcal infections
Most Recent Events
- 31 Mar 2021 Launched for Pneumococcal infections (In adolescents, In children, In the elderly, Prevention, In adults) in China (IM) - First global launch
- 09 Dec 2020 Registered for Pneumococcal infections (In adolescents, In children, In the elderly, Prevention, In adults) in China (IM) - First global approval
- 09 Dec 2020 NMPA issues product license for pneumococcal polysaccharide vaccine for prevention of streptococcus pneumonia in China